Shopping Cart
Remove All
Your shopping cart is currently empty
Bersanlimab (Synonyms: BI-505)
Catalog No. T76927 Copy Product Info
🥰Excellent
Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1), demonstrating anticancer properties and applicable for studying relapsed/refractory multiple myeloma.
Bersanlimab
Copy Product Info🥰Excellent
Catalog No. T76927
Synonyms BI-505
Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1), demonstrating anticancer properties and applicable for studying relapsed/refractory multiple myeloma.
Cas No. 1987854-08-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | In Stock | In Stock | |
| 5 mg | $689 | In Stock | In Stock | |
| 10 mg | $1,070 | - | In Stock | |
| 25 mg | $1,590 | - | In Stock | |
| 50 mg | $2,150 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1), demonstrating anticancer properties and applicable for studying relapsed/refractory multiple myeloma. |
| In vitro | Bersanlimab(BI-505) induces dose-dependent expression of ICAM-1 and programmed cell death (PCD) in Ramos, Raji, and Daudi lymphoma cells, with a dosage range spanning from 1 ng/mL to 1000 μg/mL [1]. |
| In vivo | Bersanlimab (BI-505), administered at a dose of 20 mg/kg via intraperitoneal injection twice a week for a continuous period of 21 days, significantly reduces tumor growth and prolongs the survival of animals [1]. |
| Synonyms | BI-505 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | ICAM1/CD54 |
| Molecular Weight | 144.22 kDa |
| Cas No. | 1987854-08-9 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Bersanlimab | purchase Bersanlimab | Bersanlimab cost | order Bersanlimab | Bersanlimab chemical structure | Bersanlimab in vivo | Bersanlimab in vitro | Bersanlimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.